SureTrader SureTrader SureTrader
Home > Boards > US OTC > Medical - Drugs >

Elite Pharmaceuticals (ELTP)

Add ELTP Price Alert      Hide Sticky   Hide Intro
Moderator: Mocha Jet, Drugdoctor, joseytheoutlawwales, lasers, John_Langston, IB_
Search This Board:
Last Post: 1/22/2017 11:16:04 AM - Followers: 832 - Board type: Free - Posts Today: 17

Elite Pharmaceuticals is a specialty pharmaceutical company specializing in niche generics and committed to the development of abuse-deterrent opioids to help curb diversion, misuse and abuse.  Elite has a pipeline of opioid abuse-deterrent products under development utilizing the company’s proprietary pharmacological abuse-deterrent technology.

Elite’s website can be found by going to

How ART Works:

Elite’s proprietary abuse-deterrent technology, ART™, is a multi-particulate capsule which contains an opioid agonist in addition to naltrexone, an opioid antagonist used primarily in the management of alcohol dependence and opioid dependence. When this product is taken as intended, the naltrexone is designed to pass through the body unreleased while the opioid agonist releases over time providing therapeutic pain relief for which it is prescribed. If the multi-particulate beads are crushed or dissolved, the opioid antagonist, naltrexone, is designed to release. The absorption of the naltrexone is intended to block the euphoria by preferentially binding to same receptors in the brain as the opioid agonist and thereby reducing the incentive for abuse or misuse by recreational drug abusers. Elite’s pharmacological approach to abuse-deterrence can be applied to a wide range of opioids used today in pain management.


Recent Press Releases:

Oct 21, 2015
Elite Pharmaceuticals Announces Positive Top-Line Results From a Pivotal Phase 3 Study for Abuse-Deterrent Opioid ELI-200

Aug 10, 2015
Elite Pharmaceuticals Reports Record Revenues for First Quarter of Fiscal Year 2016

Aug 3, 2015
Elite Pharmaceuticals Completes Enrollment and Dosing for ELI-200 Phase III Efficacy Trial

Jun 16, 2015
Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology

Jun 9, 2015
Elite Pharmaceuticals and Epic Pharma Enter Into a Sales and Distribution Licensing Agreement for Abuse-Deterrent ELI-200

More information can be found by going to Elite’s investor section:
Highlights From Last Quarter:
Second quarter ending September, 2015
Consolidated revenues for the second quarter of fiscal 2015 was $2.7M, all of which came from Elite's generic operation. An increases of 30% over last quarter's generic revenues. Generic revenue continues to grow with new highs being set  8 out of the 10 last quarters. The cost of revenue for this quarter totals $1.4M, for a gross profit of $1.3M. Overall expenses for the quarter total $5.3M with $4.2M going towards the development of Elite’s proprietary abuse-deterrent opioid product,ELI-200.
Business Update
The first product to utilize Elite's abuse deterrent technology, ELI-200, has successfully completed Phase III studies. The Company believes that it will be able to file a New Drug Application (NDA) with the FDA during this calendar year. When this application is accepted by the FDA it will be granted expedited review by the FDA,the company estimates that approval could be achieved in calender Q2\2016. Shareholders will be notified when the FDA accepts the ELI-200 NDA which is estimated to be in the first or second week in Jan, 2016.
Common shares issued pursuant to the strategic alliance agreement with Epic Investments LLC.
As per the Epic Strategic Alliance, Elite is entitled to 15% of the profits achieved from the commercial sales of Epic's immediate release oxycodone tablets, for a 10 year period commencing on the date of first commercial shipment and Epic is to receive 3 million shares of Common Stock upon approval by the FDA of the ANDA.




President & Chief Executive Officer - Nasrat Hakim

Nasrat Hakim joined Elite in August 2013 as Director, President and Chief Executive Officer. Mr. Hakim has more than 30 years of pharmaceutical and medical industry experience in Quality Assurance, Analytical Research and Development, Technical Services and Regulatory Compliance. He brings with him proven management experience, in-depth knowledge of manufacturing systems, development knowledge in immediate and extended release formulations and extensive regulatory experience of GMP and FDA regulations. Prior to his leading Elite, from 2004 to 2013, Mr. Hakim was employed by Actavis, Watson and Alpharma in various senior management positions. Most recently, Mr. Hakim served as International Vice President of Quality Assurance at Actavis, overseeing 25 sites with more than 3,000 employees under his leadership. Mr. Hakim also served as Corporate Vice President of Technical Services, Quality and Regulatory Compliance for Actavis U.S., Global Vice President, Quality and Regulatory Compliance for Alpharma, as well as Executive Director of Quality Unit at TheraTech, overseeing manufacturing and research and development. In 2009, Mr. Hakim founded Mikah Pharma, LLC, a virtual, fully functional pharmaceutical company.

Mr. Hakim’s career started in Medical Laboratory Technology from the Academy of Health and Sciences in the U.S. Army based in San Antonio, TX, followed by Graduate Certification in Regulatory Affairs (RAC) from California State University at Sacramento, Sacramento, CA; Bachelor in Chemistry/Bio-Chemistry and Masters of Science in Chemistry from California State University at Sacramento, Sacramento, CA; and a Masters in Law with Graduate Certification in U.S. Taxation from St. Thomas University, School of Law, Miami, FL.

Board of Directors Chairman - Jerry Treppel

Mr. Treppel is currently a Managing Director of ArcLight Advisors, an investment bank specializing in the health care sector. From October 2008 through March 2013, Mr. Treppel was Managing Director of Ledgemont Capital Group LLC, a boutique merchant bank that provided access to capital and corporate advisory services to public and private companies. Additionally, he served as the managing member of Wheaten Capital Management LLC, a capital management company focusing on investments in the health care sector from 2003 to 2008. Over the past 20 years, Mr. Treppel was an equity research analyst focusing on the specialty pharmaceuticals and generic drug sectors at several investment banking firms including Banc of America Securities, Warburg Dillon Read LLC (now UBS), and Kidder Peabody and Co. He previously served as a healthcare services analyst at various firms, including Merrill Lynch & Co. Mr. Treppel holds a BA in Biology from Rutgers College, an MHA in Health Administration from Washington University, and an MBA in Finance from New York University. Mr. Treppel has been a Chartered Financial Analyst *CFA) since 1988.

Investor Relations:

Vice President of Investor Relations and Corporate - Dianne Will

Dianne Will joined Elite in 2003 as an Investor Relations Specialist and was named Elite’s Vice President of Investor Relations and Corporate Affairs in 2013. In 1996, Ms. Will founded Willstar Consultants, an investor relations consulting firm and has been providing investor relations services to a range of public companies for more than 19 years with a primary focus in the pharmaceutical and tech sectors. Her firm provides corporate services including management and execution of investor relations programs, investor communication, peer research, compliance services, support for
management team changes, proxy fights, crisis management and IPOs.

Investor Relations and Corporate Inquiries

Dianne Will
Vice President of Investor Relations and Corporate Affairs
Telephone: 518-398-6222
Email: [email protected]

Corporate Headquarters

165 Ludlow Avenue
Northvale, New Jersey 07647
Phone: 201-750-2646
Fax: 201-750-2755

Miscellaneous Links:

SEC Filings:

FDA website:

Clinical Trials.Gov:


  Using the industry average PE\Ratio of 15, an over exaggerated  share count of 100% of the 995M authorized shares, and a very conservative
  profit margin of 30%, Elite stands to garner an increase in share price with the launch of each abuse resistant opioid product.


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
ELTP News: Current Report Filing (8-k) 12/22/2016 05:25:52 PM
ELTP News: Confidential Treatment Order (ct Order) 12/22/2016 05:17:13 PM
ELTP News: Amended Annual Report (10-k/a) 11/17/2016 04:05:38 PM
ELTP News: Amended Quarterly Report (10-q/a) 11/17/2016 04:03:30 PM
ELTP News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 11/09/2016 05:10:17 PM
#239843  Sticky Note Maz, this has nothing to do with SequestOx WeeZuhl 01/20/17 08:56:19 PM
#239443  Sticky Note Yes IMO first SequestOx FDA Commercial approval in lasers 01/17/17 11:02:44 PM
#236265  Sticky Note Elite Pharma: The company of firsts: namtae 12/14/16 12:32:00 PM
#234937  Sticky Note THIS IS WHAT YOU NEED TO KNOW BEFORE Couch 11/30/16 03:04:07 PM
#189564  Sticky Note $ELTP SequestOx and ADF Patents lasers 03/18/16 04:29:26 AM
#185967  Sticky Note The only topic here is ELTP. IH Admin [Dan] 02/23/16 09:32:46 PM
#239933   Don, don't waste your time unless he posts pte 01/22/17 11:16:04 AM
#239932   Link please Padin 01/22/17 11:06:57 AM
#239930   And by the way, some more info for doncamel 01/22/17 10:31:56 AM
#239929   Yes there is that possibility that for an lasers 01/22/17 10:31:27 AM
#239926   They're not gonna post the transcripts, if you doncamel 01/22/17 10:22:01 AM
#239924   doncamel nothing yet posted on the FDA website lasers 01/22/17 10:18:30 AM
#239923   About 200k shares were SOLD in the last namtae 01/22/17 10:10:45 AM
#239922   “Following our recent announcement regarding a successful FDA sharkey1 01/22/17 09:42:21 AM
#239921   About 200k shares were purchased in the last doncamel 01/22/17 09:38:29 AM
#239918   Possibly Trump will be the best thing only rocioyogi 01/22/17 08:04:39 AM
#239917   Trump could be the best thing for little sharkey1 01/22/17 06:40:03 AM
#239916   k mrwrn2010 01/21/17 10:07:41 PM
#239915   Not from me you didn't. I never said dr_lowenstein 01/21/17 10:07:00 PM
#239914   What happened to guaranteed single digits after the mrwrn2010 01/21/17 10:05:39 PM
#239913   Been hearing guaranteed bankruptcy since .04. Wrong! mrwrn2010 01/21/17 10:03:50 PM
#239912   Elite will become a leader in the abuse NASDAQ2020 01/21/17 09:23:12 PM
#239911   I agree. That's why Elite put the aELmTPa 01/21/17 09:20:34 PM
#239910   All of BIG PHARMA must be scrambling all namtae 01/21/17 08:30:30 PM
#239909   Been hearing about this guaranteed stock since .97. Sad dr_lowenstein 01/21/17 08:09:10 PM
#239908   So is the same as GUARANTEED approval like stockboy 01/21/17 07:51:58 PM
#239907   Elite will have to stock 67,000 US pharmacies NASDAQ2020 01/21/17 06:41:45 PM
#239906   "the FDA made no comment about Elite’s technology NASDAQ2020 01/21/17 06:40:45 PM
#239905   "the FDA made no comment about Elite’s technology NASDAQ2020 01/21/17 06:40:13 PM
#239904   Elite owns the Holy Grail for ADF Immediate NASDAQ2020 01/21/17 06:39:24 PM
#239903   Monthly trend ELTP NASDAQ2020 01/21/17 06:37:52 PM
#239902   maybe we should give the rookie CEO some dr_lowenstein 01/21/17 05:27:06 PM
#239901   un·re·al ??n're(?)l/Submit adjective so strange as to appear imaginary; not s dr_lowenstein 01/21/17 04:54:46 PM
#239899   Anytime you find a CEO like Nasrat running Couch 01/21/17 04:46:59 PM
#239898   LOL yes all that is NOT REAL, thanks dr_lowenstein 01/21/17 04:45:52 PM
#239897   SequestOx PR next week detailing successful FDA meeting. aELmTPa 01/21/17 04:16:49 PM
#239896   Anytime you find a noob, beginner CEO like namtae 01/21/17 04:00:47 PM
#239895   Savvy investors dont really care when these minutes dr_lowenstein 01/21/17 03:55:31 PM
#239894   No Kidding, REALLY, the 31st is the end greenlife 01/21/17 03:37:50 PM
#239893   Heard all that at .04 tho mrwrn2010 01/21/17 03:27:30 PM
#239888 stockboy 01/21/17 02:02:02 PM
#239887   Nasrat and team maybe working on it as kennyt 335 01/21/17 12:01:37 PM
#239886   Mocha, true, but most of them are referring freegriff 01/21/17 11:55:42 AM
#239885   "...The FDA will provide minutes of the meeting Mocha Jet 01/21/17 11:03:46 AM
#239884   WHOOPSY actual FDA FACTS say that is FOS Couch 01/21/17 10:33:19 AM
#239883   Trust me when I say Elite shares are namtae 01/21/17 10:21:03 AM
#239881   What has NasRAT produced besides a bunch of stockboy 01/21/17 09:50:22 AM
#239880   Oh I hope you are right. The longer Gman24 01/21/17 09:46:56 AM
#239879   Soon Elite holders will be looking forward to namtae 01/21/17 09:43:41 AM
#239878   Weezuhl what a informative post a positive path alfonso31 01/21/17 09:42:59 AM
#239877   Bingo Couch... Elite's generic pipeline are no longer Gman24 01/21/17 09:33:35 AM
#239876   Elite is another penny stock story to gather namtae 01/21/17 09:16:47 AM
#239874   LMMFAO!!!! "We are extremely pleased that there Couch 01/21/17 08:01:35 AM
#239873   Elite Pharma: The company of firsts: stockboy 01/21/17 07:48:08 AM
#239871   Seven Pathways to Dollarland NASDAQ2020 01/21/17 07:40:53 AM
#239870   40,000 ER docs in the U.S. with at NASDAQ2020 01/21/17 07:23:56 AM